Search

Your search keyword '"C5a"' showing total 109 results

Search Constraints

Start Over You searched for: Descriptor "C5a" Remove constraint Descriptor: "C5a" Topic complement activation Remove constraint Topic: complement activation
109 results on '"C5a"'

Search Results

1. Dysregulated complement activation during acute myocardial infarction leads to endothelial glycocalyx degradation and endothelial dysfunction via the C5a:C5a-Receptor1 axis.

2. Antiphospholipid antibody carriers and patients with quiescent antiphospholipid syndrome show persistent subclinical complement activation.

3. Complement System Inhibitory Drugs in a Zebrafish ( Danio rerio ) Model: Computational Modeling.

4. C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d.

5. Sepsis target validation for repurposing and combining complement and immune checkpoint inhibition therapeutics.

6. Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19.

7. Complement activation and endothelial perturbation parallel COVID-19 severity and activity.

8. The rise of complement in ANCA-associated vasculitis: from marginal player to target of modern therapy.

9. Complement in sepsis-when science meets clinics.

10. C5aR1 Activation Drives Early IFN-γ Production to Control Experimental Toxoplasma gondii Infection.

11. Editorial: The Role of Complement in Tumors.

12. Complement activation products in the circulation and urine of primary membranous nephropathy.

13. Anti-C5a complementary peptide mitigates zymosan-induced severe peritonitis with fibrotic encapsulation in rats pretreated with methylglyoxal.

14. Intracellular complement activation-An alarm raising mechanism?

15. Complement Activation During Ischemia/Reperfusion Injury Induces Pericyte-to-Myofibroblast Transdifferentiation Regulating Peritubular Capillary Lumen Reduction Through pERK Signaling.

16. IL-17A deficiency mitigates bleomycin-induced complement activation during lung fibrosis.

17. Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses.

18. New concepts on the therapeutic control of complement anaphylatoxin receptors.

19. Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs.

20. Time-course analysis of C3a and C5a quantifies the coupling between the upper and terminal Complement pathways in vitro.

21. Treatment of platelets with riboflavin and ultraviolet light mediates complement activation and suppresses monocyte interleukin-12 production in whole blood.

22. Crosstalk between TGF-β1 and complement activation augments epithelial injury in pulmonary fibrosis.

23. Complement activation and liver impairment in trichloroethylene-sensitized BALB/c mice.

24. Soluble terminal complement complex blood levels are elevated in schizophrenia.

25. Cell-intrinsic C5a synergizes with Dectin-1 in macrophages to mediate fungal killing.

26. Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy.

27. C5aR2 Regulates STING-Mediated Interferon Beta Production in Human Macrophages.

28. Effects of heat shock protein 90 on complement activation in myocardial ischemia/reperfusion injury after pioglitazone preconditioning.

29. Increased Expression of Anaphylatoxin C5a-Receptor-1 in Neutrophils and Natural Killer Cells of Preterm Infants.

30. Complement Activation Products in Patients with Chronic Schizophrenia.

31. Complement activation contributes to subretinal fibrosis through the induction of epithelial-to-mesenchymal transition (EMT) in retinal pigment epithelial cells.

32. Modulation of C5a–C5aR1 signaling alters the dynamics of AD progression.

33. The Complement System and ANCA Associated Vasculitis in the Era of Anti-Complement Drugs.

34. Chapter Three - Complement as a powerful "influencer" in the brain during development, adulthood and neurological disorders.

35. Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA1 Antibody in IgA Nephropathy Patients.

36. The effects of tidal volume size and driving pressure levels on pulmonary complement activation: an observational study in critically ill patients.

37. The relationship of anti-phospholipase A2 receptor antibody and C5a complement with disease activity and short-term outcome in idiopathic membranous nephropathy.

38. Complement C5a is present in CSF of human newborns and is elevated in association with preterm birth.

39. The anaphylatoxin C5a: Structure, function, signaling, physiology, disease, and therapeutics.

40. Complement activation contributes to subretinal fibrosis through the induction of epithelial-to-mesenchymal transition (EMT) in retinal pigment epithelial cells

41. Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19

42. Neutrophil-activating therapy for the treatment of cancer.

43. Complement activation in patients with COVID-19: A novel therapeutic target

44. The complement system as a regulator of tumor-promoting activities mediated by myeloid-derived suppressor cells.

45. Complement system activation in ANCA vasculitis: A translational success story?

46. Complement cascade in severe forms of COVID-19: Recent advances in therapy

47. Complement Regulation in Human Tenocytes under the Influence of Anaphylatoxin C5a

48. Biomechanische Eigenschaften von neutrophilen Granulozyten unter der Stimulation mit dem Anaphylatoxin C5a

49. Involvement of complement peptides C3a and C5a in osteoarthritis pathology.

50. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Catalog

Books, media, physical & digital resources